JP2017529074A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529074A5
JP2017529074A5 JP2017513004A JP2017513004A JP2017529074A5 JP 2017529074 A5 JP2017529074 A5 JP 2017529074A5 JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017529074 A5 JP2017529074 A5 JP 2017529074A5
Authority
JP
Japan
Prior art keywords
mrna
cancer
ercc1 isoform
therapeutic agent
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513004A
Other languages
English (en)
Japanese (ja)
Other versions
JP7057668B2 (ja
JP2017529074A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071170 external-priority patent/WO2016042009A1/en
Publication of JP2017529074A publication Critical patent/JP2017529074A/ja
Publication of JP2017529074A5 publication Critical patent/JP2017529074A5/ja
Application granted granted Critical
Publication of JP7057668B2 publication Critical patent/JP7057668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513004A 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 Active JP7057668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185247.5 2014-09-18
EP14185247 2014-09-18
PCT/EP2015/071170 WO2016042009A1 (en) 2014-09-18 2015-09-16 Mrna and/or protein of ercc1 isoform 3 for use in diagnosing a resistance against a therapeutic agent and method for diagnosing a resistance against a therapeutic agent using said mrna and/or protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168483A Division JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Publications (3)

Publication Number Publication Date
JP2017529074A JP2017529074A (ja) 2017-10-05
JP2017529074A5 true JP2017529074A5 (enExample) 2018-08-23
JP7057668B2 JP7057668B2 (ja) 2022-04-20

Family

ID=51542262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513004A Active JP7057668B2 (ja) 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Country Status (4)

Country Link
US (1) US20170233826A1 (enExample)
EP (1) EP3194616B1 (enExample)
JP (2) JP7057668B2 (enExample)
WO (1) WO2016042009A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067998A1 (en) * 2017-06-20 2018-12-27 Nantomics, Llc Use of cell-free circulating rna (cfrna) expression of pd-l1 and ercc1 in plasma to monitor response to therapy in nsclc
KR102780643B1 (ko) * 2020-11-04 2025-03-17 한국과학기술원 비기능성 전사체를 이용한 parp 저해제 또는 dna 손상 약물 감수성 판정방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253533T3 (es) * 2001-09-06 2006-06-01 Adnagen Ag Procedimiento para la deteccion cualitativa y/o cuantitativa de celulas.
US9702875B2 (en) * 2006-03-14 2017-07-11 Institute Gustave-Roussy Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
MX2008013332A (es) * 2006-04-18 2008-11-10 Wellstat Biologics Corp Deteccion de proteinas de celulas neoplasicas circulantes.
EP2233589A1 (en) * 2009-03-19 2010-09-29 Institut Gustave Roussy MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
AU2010289448A1 (en) * 2009-09-03 2012-03-22 The Scripps Research Institute Method for categorizing circulating tumor cells
WO2012051390A1 (en) * 2010-10-14 2012-04-19 Veridex, Llc Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents

Similar Documents

Publication Publication Date Title
Zhao et al. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application
M Braden et al. Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence
Ahlin et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
Anantharaman et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
Chundong et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis
Li et al. Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
EP3488238B1 (en) Combination test for colorectal cancer
AU2013263337A1 (en) Tumor cell isolation/purification process and methods for use thereof
Luo et al. Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
Minamoto et al. Loss of beclin 1 expression in ovarian cancer: A potential biomarker for predicting unfavorable outcomes
Chen et al. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
Pontikakis et al. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy
Shi et al. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma
Wang et al. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy
Gheni et al. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings
Aufderklamm et al. XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence
EP3545108A1 (en) Biomarkers for the prognosis and diagnosis of cancer
Jiang et al. Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer
JP2017529074A5 (enExample)
JP2021019612A (ja) 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
Droeser et al. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells
Ciccarese et al. Circulating tumor cells: a reliable biomarker for prostate cancer treatment assessment?
Yau et al. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays
EP2574929A1 (en) Marker in diagnosing prostate cancer (PC)
EP2320235A1 (en) Marker for prostate cancer diagnosis